Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
The DOI matches its Crossref record; 281 of the 281 references it cites were found in a registry or an index.
Abstract
Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters. Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small molecules. This Review discusses the role of altered expression and/or function of one class of epigenetic regulators--histone deacetylases (HDACs)--and their role in cancer, neurological diseases and immune disorders. We highlight the development of small-molecule HDAC inhibitors and their use in the laboratory, in preclinical models and in the clinic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is increasing evidence that KDAC inhibitors work best in combination with other therapies [28–30]”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [29]
In the citing paper
“Growing evidence supports that epigenetic dysregulation through histone deacetylases (HDACs) plays a critical role in synaptic dysfunction and memory loss in Alzheimer’s disease”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDAC inhibitors can enhance histone acetylation and ameliorate cognitive impairments in various AD models, and HDAC inhibition has been recognized as an attractive therapeutic strategy for AD [4, 5, 7].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDAC inhibitors can enhance histone acetylation and ameliorate cognitive impairments in various AD models, and HDAC inhibition has been recognized as an attractive therapeutic strategy for AD [4, 5, 7].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDACs are epigenetic modulators that deacetylate lysine residues in histone and nonhistone substrates and their inhibition has attracted much interest for the treatment of neurodegenerative disorders, as several isoforms seem to be implicated in AD memory-related dysfunction: HDAC2 is a nuclear isoform that reduce transcription of CREB-regulated genes involved in learning and memory, HDAC6 targets”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [118]
Citations
Cites
4 retracted
Zhang, X., Zhao, X., Fiskus, W., Lin, J., Lwin, T., Rao, R., Zhang, Y., Chan, J. C., Fu, K., Marquez, V. E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.003 · Cited by 276
RetractedChen, C.-S., Wang, Y.-C., Yang, H.-C., Huang, P.-H., Kulp, S. K., Yang, C.-C., Lu, Y.-S., Matsuyama, S., Chen, C.-Y., & Chen, C.-S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3996 · Cited by 187
RetractedDasmahapatra, G. P., Lembersky, D., Kramer, L. B., Fisher, R. I., Friedberg, J. W., Dent, P., & Grant, S. (2010) · Blood · doi:10.1182/blood-2009-12-257261 · Cited by 115
RetractedDasmahapatra, G. P., Lembersky, D., Son, M. P., Attkisson, E., Dent, P., Fisher, R. I., Friedberg, J. W., & Grant, S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1108 · Cited by 62
RetractedChromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
Jaenisch, R., & Bird, A. (2003) · Nature Genetics · doi:10.1038/ng1089 · Cited by 6,325
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 3×
“AML1 and the AML1–ETO fusion protein in the pathogenesis of t(8;21) AML.”
BackgroundLysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Cited by
Items 101–200 of 1,003
Li, Y., Lu, B., Sheng, L., Zhu, Z., Sun, H., Zhou, Y., Yang, Y., Xue, D., Chen, W., Tian, X., et al. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14267 · Cited by 156
Histone deacetylase function in CD4+ T cells
Ellmeier, W., & Seiser, C. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0037-z · Cited by 154
Structure, mechanism, and inhibition of the zinc-dependent histone deacetylases
Porter, N. J., & Christianson, D. W. (2019) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2019.01.004 · Cited by 146
Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs
Brien, G. L., Valerio, D. G., & Armstrong, S. A. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.007 · Cited by 169
Davis, F. M., & Gallagher, K. A. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.312135 · Cited by 166
Chemical genomics reveals histone deacetylases are required for core regulatory transcription
Gryder, B. E., Wu, L., Woldemichael, G. M., Pomella, S., Quinn, T. R., Park, P. M. C., Cleveland, A., Stanton, B. Z., Song, Y., Rota, R., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11046-7 · Cited by 144
Enteric nervous system: the bridge between the gut microbiota and neurological disorders
Geng, Z.-H., Zhu, Y., Li, Q.-L., Zhao, C., & Zhou, P.-H. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.810483 · Cited by 144
“The inhibition of HDACs enhances the histone acetylation of gene regulatory elements and increases gene transcription (Falkenberg and Johnstone, 2014).”
BackgroundNext-generation of selective histone deacetylase inhibitors
Yang, F., Zhao, N., Ge, D., & Chen, Y. (2019) · RSC Advances · doi:10.1039/c9ra02985k · Cited by 155
Histone deacetylase 11 is an ε-N-Myristoyllysine hydrolase
Moreno-Yruela, C., Galleano, I., Madsen, A. S., & Olsen, C. A. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.04.007 · Cited by 149
Aggregation‐Induced Emission Luminogens: Union Is Strength, Gathering Illuminates Healthcare
Qi, J., Chen, C., Ding, D., & Tang, B. Z. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800477 · Cited by 146
Arboleda, V. A., Lee, H., Dorrani, N., Zadeh, N., Willis, M. J. H., Macmurdo, C., Manning, M. A., Hanson‐Kahn, A., Hudgins, L., Barthélémy, F., et al. (2015) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.01.017 · Cited by 161
LncMAP: Pan-cancer atlas of long noncoding RNA-mediated transcriptional network perturbations
Li, Y., Li, X., Wang, Z., Pan, T., Sahni, N., Jin, X., Wang, G., Li, J., Zheng, X., Zhang, Y., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1311 · Cited by 140
Millard, C. J., Varma, N., Saleh, A., Morris, K., Watson, P. J., Bottrill, A. R., Fairall, L., Smith, C. J., & Schwabe, J. W. (2016) · eLife · doi:10.7554/elife.13941 · Cited by 139
Daskalaki, M., Tsatsanis, C., & Kampranis, S. C. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26497 · Cited by 147
“HDAC3 negatively regulates NF-kB signaling indirectly by deacetylating the p65 subunit, promoting interaction of p65 with the inhibitory subunit NF-kB inhibitor-α (IκΒα) (Falkenberg & Johnstone, 2014).”
BackgroundRecent Progress in Histone Deacetylase Inhibitors as Anticancer Agents
Cappellacci, L., Perinelli, D. R., Maggi, F., Grifantini, M., & Petrelli, R. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181016163110 · Cited by 147
Zhong, H.-J., Lu, L., Leung, K.-H., Wong, C. C. L., Peng, C., Yan, S.-C., Ma, D.-L., Cai, Z., David Wang, H.-M., & Leung, C.-H. (2015) · Chemical Science · doi:10.1039/c5sc02321a · Cited by 138
Epigenetic regulation of gene expression in cancer: techniques, resources and analysis
Kagohara, L. T., Stein-O’Brien, G., Kelley, D. Z., Flam, E. L., Wick, H. C., Danilova, L., Easwaran, H., Favorov, A. V., Qian, J. X., Gaykalova, D. A., et al. (2017) · Briefings in Functional Genomics · doi:10.1093/bfgp/elx018 · Cited by 149
Cheng, H., Liu, J., Tan, Y., Feng, W., & Peng, C. Y. (2021) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2021.10.003 · Cited by 150
Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
Banik, D., Moufarrij, S., & Villagra, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092241 · Cited by 147
“Vorinostat is the first pan-HDACi to be approved for the treatment of relapsed and refractory cutaneous T cell lymphoma, and romidepsin, a pan-HDACi, is approved for the treatment of peripheral T cell lymphoma [47].”
BackgroundRecent Findings in the Regulation of Programmed Death Ligand 1 Expression
Shen, X., Zhang, L., Li, J., Li, Y., Wang, Y., & Xu, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01337 · Cited by 139
“Histone deacetylases (HDACs) have pleiotropic efficiency in regulating immune response (81).”
BackgroundGlioblastoma Treatment Modalities besides Surgery
Zhang, H., Wang, R., Yu, Y., Liu, J., Luo, T., & Fan, F. (2019) · Journal of Cancer · doi:10.7150/jca.32475 · Cited by 150
“Among kinds of epigenetic drugs against GBM, histone deacetylase (HDAC) inhibitors have drawn the most attention due to its broad mechanisms including cell-cycle arrest induction, differentiation, senescence, intrinsic and extrinsic apoptosis, mitotic cell death, autophagic cell death, inhibition of angiogenesis and m…”
BackgroundAdvances in epigenetic therapeutics with focus on solid tumors
Jin, N. Y., George, T. L., Otterson, G. A., Verschraegen, C. F., Wen, H., Carbone, D. P., Herman, J. G., Bertino, E. M., & He, K. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01069-7 · Cited by 142
“There are four classes of HDAC enzymes based on their structures and functions: class I (HDAC 1–3 and 8), IIa (HDAC 4, 5, 7, 9), IIb (HDAC 6, 10), III (Sir-2 related—SIRT1-7) and IV (HDAC 11) [20, 21].”
BackgroundSodium butyrate alleviates adipocyte inflammation by inhibiting NLRP3 pathway
Wang, X., He, G., Peng, Y., Zhong, W., Wang, Y., & Zhang, B. (2015) · Scientific Reports · doi:10.1038/srep12676 · Cited by 134
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors
Bass, A. K. A., El‐Zoghbi, M. S., Nageeb, E.-S. M., Mohamed, M. F. A., Badr, M., & Abuo‐Rahma, G. E. A. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112904 · Cited by 132
Marek, M., Shaik, T. B., Heimburg, T., Chakrabarti, A., Lancelot, J., Ramos-Morales, E., Da Veiga, C., Kalinin, D., Melesina, J., Robaa, D., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01087 · Cited by 122
“We have used another benzohydroxamate inhibitor (11) which has an internal amine rather than an”
MethodEpigenetic Regulation of Monocyte and Macrophage Function
Hoeksema, M. A., & de Winther, M. P. J. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6695 · Cited by 134
McCluskey, S. P., Plisson, C., Rabiner, E. A., & Howes, O. D. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04488-0 · Cited by 135
PROTAC-mediated degradation of class I histone deacetylase enzymes in corepressor complexes
Smalley, J. P., Adams, G. E., Millard, C. J., Song, Y., Norris, J. K. S., Schwabe, J. W. R., Cowley, S. M., & Hodgkinson, J. T. (2020) · Chemical Communications · doi:10.1039/d0cc01485k · Cited by 121
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies
Amodio, N., Rossi, M., Raimondi, L., Pitari, M. R., Botta, C., Tagliaferri, P., & Tassone, P. (2015) · Oncotarget · doi:10.18632/oncotarget.3805 · Cited by 131
Shahbazi, J., Liu, P. Y., Atmadibrata, B., Bradner, J. E., Marshall, G. M., Lock, R. B., & Liu, T. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1666 · Cited by 124
HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma
Wang, Z., Hu, P., Tang, F., Lian, H., Chen, X., Zhang, Y., He, X., Liu, W., & Xie, C. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.06.001 · Cited by 128
The Emerging Role of Epigenetics in Inflammation and Immunometabolism
Raghuraman, S., Donkin, I., Versteyhe, S., Barrès, R., & Simar, D. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.06.008 · Cited by 124
Bivalent Ligands for Protein Degradation in Drug Discovery
Scheepstra, M., Hekking, K. F. W., Hijfte, L. V., & Folmer, R. H. A. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.01.006 · Cited by 135
“HDACs are epigenetic erasers, which control gene transcription via the removal of epigenetic markers, that play crucial roles in many diseases [76].”
BackgroundStrategies for designing proteolysis targeting chimaeras (PROTACs)
He, S., Dong, G., Cheng, J., Wu, Y., & Sheng, C. (2022) · Medicinal Research Reviews · doi:10.1002/med.21877 · Cited by 108
“HDAC plays an important role in regulating chromatin structure, transcription factors, and nonhistone functions.(188) Five HDAC inhibitors have been approved as therapeutic antitumor agents.”
BackgroundBasal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond
Bakshi, A., Chaudhary, S. C., Rana, M., Elmets, C. A., & Athar, M. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22690 · Cited by 135
Yang, W., Li, Y., Gao, R., Xiu, Z., & Sun, T. (2019) · Oncogene · doi:10.1038/s41388-019-1045-6 · Cited by 121
Moufarrij, S., Srivastava, A., Gomez, S., Hadley, M. M., Palmer, E., Austin, P. T., Chisholm, S., Diab, N., Roche, K. C., Yu, A. Y. C., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-60409-4 · Cited by 126
Yang, K., Wu, H., Zhang, Z., Leisten, E. D., Nie, X., Liu, B., Wen, Z., Zhang, J., Cunningham, M. D., & Tang, W. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00046 · Cited by 124
Bromodomain Histone Readers and Cancer
Jain, A. K., & Barton, M. C. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.11.020 · Cited by 123
5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy
Vasanthakumar, A., & Godley, L. A. (2015) · Cancer Genetics · doi:10.1016/j.cancergen.2015.02.009 · Cited by 128
Gupta, K. D., Shakespear, M. R., Iyer, A., Fairlie, D. P., & Sweet, M. J. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2015.46 · Cited by 124
Zhang, J., Wang, J., Zhou, Z., Park, J.-E., Wang, L., Wu, S., Sun, X., Lu, L., Wang, T., Lin, Q., et al. (2018) · Autophagy · doi:10.1080/15548627.2018.1447290 · Cited by 44
Microbial Metabolites, Postbiotics, and Intestinal Epithelial Function
Mayorgas, A., Dotti, I., & Salas, A. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202000188 · Cited by 138
Role of epigenetic regulation in myocardial ischemia/reperfusion injury
Wang, K., Li, Y., Qiang, T., Chen, J., & Wang, X. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105743 · Cited by 124
Rodrigues, D. A., Ferreira‐Silva, G. Á., Ferreira, A. C. S., Fernandes, R. A., Kwee, J. K., Sant’Anna, C. M. R., Ionta, M., & Fraga, C. A. M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01525 · Cited by 119
Ciarlo, E., Heinonen, T., Herderschee, J., Fenwick, C. W., Mombelli, M., Roy, D. L., & Roger, T. (2016) · Scientific Reports · doi:10.1038/srep37944 · Cited by 132
Histone Deacetylase 9 Activates IKK to Regulate Atherosclerotic Plaque Vulnerability
Asare, Y., Campbell-James, T. A., Bokov, Y., Yu, L. L., Prestel, M., Bounkari, O. E., Roth, S., Megens, R. T. A., Straub, T., Thomas, K., et al. (2020) · Circulation Research · doi:10.1161/circresaha.120.316743 · Cited by 123
Zang, J., Liang, X., Huang, Y., Jia, Y., Li, X., Xu, W., Chou, C. J., & Zhang, Y. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00384 · Cited by 114
Yang, Z., Wang, T., Wang, F., Niu, T., Liu, Z., Chen, X. L., Long, C., Tang, M., Cao, D., Wang, X., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01342 · Cited by 114
Kim, D. S., Kwon, J.-E., Lee, S. H., Kim, E. K., Ryu, J.-G., Jung, K.-A., Choi, J.-W., Park, M.-J., Moon, Y.-M., Park, S.-H., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01525 · Cited by 110
“For this reason, inhibitors of HDAC are used clinically to treat various conditions (38, 39).”
BackgroundPorter, N. J., Osko, J. D., Diedrich, D., Kurz, T., Hooker, J. M., Hansen, F. K., & Christianson, D. W. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01013 · Cited by 111
How do tumor cells respond to HDAC inhibition?
Newbold, A., Falkenberg, K. J., Prince, H. M., & Johnstone, R. W. (2016) · FEBS Journal · doi:10.1111/febs.13746 · Cited by 121
Self-citationImmunomodulatory roles of microbiota-derived short-chain fatty acids in bacterial infections
Ranjbar, R., Vahdati, S. N., Tavakoli, S., Khodaie, R., & Behboudi, H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111817 · Cited by 120
Turnbull, R. E., Fairall, L., Saleh, A., Kelsall, E., Morris, K. L., Ragan, T. J., Savva, C. G., Chandru, A., Millard, C. J., Makarova, O. V., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17078-8 · Cited by 108
McClure, J. J., Zhang, C., Inks, E. S., Peterson, Y. K., Li, J., & Chou, C. J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01385 · Cited by 96
Epigenetic Mechanisms and Hypertension
Liang, M. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11171 · Cited by 117
Chua, M. J., Arnold, M. S. J., Xu, W., Lancelot, J., Lamotte, S., Späth, G. F., Prina, E., Pierce, R. J., Fairlie, D. P., Skinner‐Adams, T. S., et al. (2016) · International Journal for Parasitology Drugs and Drug Resistance · doi:10.1016/j.ijpddr.2016.12.005 · Cited by 108
Malone, C. F., Emerson, C. E., Ingraham, R., Barbosa, W. A., Guerra, S. L., Yoon, H., Liu, L. L., Michor, F., Haigis, M. C., Macleod, K. F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0177 · Cited by 113
“Vorinostat inhibits class I, II, and IV HDAC complexes; however, more selective and/or potent agents have been developed (32).”
Expanding the Genetic Code to Study Protein–Protein Interactions
Nguyen, T., Cigler, M., & Lang, K. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201805869 · Cited by 109
Zhou, X., Ni, Y., Liang, X., Lin, Y., An, B., He, X., & Zhao, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915094 · Cited by 145
Zhang, C., Wang, X., Zhang, E., Yang, L., Yuan, H., Tu, W., Zhang, H., Yin, Z., Shen, W., Chen, X., et al. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.09.036 · Cited by 107
Lanka, G., Begum, D., Banerjee, S., Adhikari, N., Yogeeswari, P., & Ghosh, B. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107481 · Cited by 112
Sun, B., Shah, B., Fiskus, W. C., Qi, J., Rajapakshe, K., Coarfa, C., Li, L., Devaraj, S. G. T., Sharma, S., Zhang, L., et al. (2015) · Blood · doi:10.1182/blood-2015-04-639542 · Cited by 120
Yakovlev, I., Carneros, E., Lee, Y., Olsen, J. E., & Fossdal, C. G. (2016) · Planta · doi:10.1007/s00425-016-2484-8 · Cited by 109
HDAC6: A Novel Histone Deacetylase Implicated in Pulmonary Arterial Hypertension
Boucherat, O., Chabot, S., Paulin, R., Trinh, I., Bourgeois, A., Potus, F., Lampron, M.-C., Lambert, C., Breuils‐Bonnet, S., Nadeau, V., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04874-4 · Cited by 107
Histone Deacetylase Inhibitors and Phenotypical Transformation of Cancer Cells
Wawruszak, A., Kałafut, J., Okoń, E., Czapiński, J., Hałasa, M., Przybyszewska-Podstawka, A., Miziak, P. A., Okła, K., Rivero‐Müller, A., & Stepulak, A. (2019) · Cancers · doi:10.3390/cancers11020148 · Cited by 106
Cancer's epigenetic drugs: where are they in the cancer medicines?
Ghasemi, S. (2019) · The Pharmacogenomics Journal · doi:10.1038/s41397-019-0138-5 · Cited by 109
Advances in epigenetic glioblastoma therapy
Lee, D. H., Ryu, H.-W., Won, H.-R., & Kwon, S. H. (2017) · Oncotarget · doi:10.18632/oncotarget.14612 · Cited by 114
Bishayee, K., Khuda‐Bukhsh, A. R., & Huh, S. (2015) · Molecules and Cells · doi:10.14348/molcells.2015.2339 · Cited by 102
Emerging Role of Epigenetic Mechanisms in Alcohol Addiction
Berkel, T. D. M., & Pandey, S. C. (2017) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.13338 · Cited by 101
Géraldy, M. N. E., Morgen, M., Sehr, P. A., Steimbach, R. R., Moi, D., Ridinger, J., Oehme, I., Witt, O., Malz, M., Nogueira, M. S., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01936 · Cited by 101
Jin, J., & Zhao, Q. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-00629-y · Cited by 108
Zhang, K., Lai, F., Lin, S., Ji, M., Zhang, J., Zhang, Y., Jin, J., Fu, R., Wu, D., Tian, H., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00390 · Cited by 101
Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade
Marchini, A., Scott, E. M., & Rommelaere, J. (2016) · Viruses · doi:10.3390/v8010009 · Cited by 118
Liang, X., Zang, J., Li, X., Tang, S., Huang, M., Geng, M., Chou, C. J., Li, C., Cao, Y.-C., Xu, W., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01597 · Cited by 102
Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors
Perrier, A., Didelot, A., Laurent‐Puig, P., Blons, H., & Garinet, S. (2020) · Biomolecules · doi:10.3390/biom10071061 · Cited by 111
“They are classified into different classes: I, IIa, IIb, III and IV and impact innate and adaptive immune responses [61,62].”
BackgroundThe Emerging Role of Epigenetics in Autoimmune Thyroid Diseases
Wang, B., Shao, X., Song, R., Xu, D., & Zhang, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00396 · Cited by 110
Krumm, A., Barckhausen, C., Kücük, P., Tomaszowski, K.-H., Loquai, C., Fahrer, J., Krämer, O. H., Kaina, B., & Roos, W. P. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2680 · Cited by 91
“In cancer cells, the inhibition of HDACs has been shown to influence the execution of the extrinsic and intrinsic apoptosis pathways as well as affecting DNA repair (21).”
Epigenetic reprogramming in liver fibrosis and cancer
Wilson, C. L., Mann, D. A., & Borthwick, L. A. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.10.011 · Cited by 96
Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified
Ji, M.-M., Huang, Y., Huang, J.-Y., Wang, Z., Fu, D., Liu, H., Liu, F., Lebœuf, C., Wang, L., Ye, J., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.182444 · Cited by 104
Gupta, K. D., Shakespear, M. R., Curson, J. E. B., Murthy, A. M. V., Iyer, A., Hodson, M. P., Ramnath, D., Tillu, V. A., von Pein, J. B., Reid, R. C., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.02.007 · Cited by 105
“In addition to their anti-cancer properties (Falkenberg and Johnstone, 2014), several broadspectrum HDACi were efficacious in animal models of inflammatory diseases (Shakespear et al.”
Hypertranscription and replication stress in cancer
Bowry, A., Kelly, R. D., & Petermann, E. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.04.006 · Cited by 120
Maertens, O., Kuzmickas, R., Manchester, H. E., Emerson, C. E., Gavin, A. G., Guild, C. J., Wong, T. C., De Raedt, T., Bowman-Colin, C., Hatchi, E., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0879 · Cited by 95
“Although single-agent efficacy in solid tumors has not been observed, HDAC inhibitors are currently being evaluated in combination with other targeted agents in several diseases (8).”
BackgroundElmezayen, A. D., & Yelekçi, K. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1798812 · Cited by 99
“In addition, it provided a great advantage for improving the drug industry and for discovering novel treatments (Falkenberg & Johnstone, 2014).”
BackgroundTang, S.-W., Thomas, A., Murai, J., Trepel, J. B., Bates, S. E., Rajapakse, V. N., & Pommier, Y. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0443 · Cited by 94
Yamakawa, H., Cheng, J., Penney, J., Gao, F., Rueda, R., Wang, J., Yamakawa, S., Kritskiy, O., Gjoneska, E., & Tsai, L. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.044 · Cited by 101
“Indeed, HDAC2 and other HDACs often interact with different binding partners and regulate distinct subsets of genes depending on cell type, developmental stage, and any number of other intrinsic or extrinsic signals (Bantscheff et al., 2011; Falkenberg and Johnstone, 2014).”
BackgroundZhang, Y., Ying, J. B., Hong, J. J., Li, F., Fu, T. T., Yang, F. Y., Zheng, G. X., Yao, X., Lou, Y., Qiu, Y., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00729 · Cited by 96
Wu, F., Zhou, C., Yao, Y., Wei, L., Feng, Z., Deng, L., & Song, Y. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01361 · Cited by 95
wang, L., Li, H., Ren, Y., Zou, S., Fang, W., Jiang, X., Li, J., Li, M., Liu, X., Yuan, X., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2015.328 · Cited by 95
A chemical probe toolbox for dissecting the cancer epigenome
Shortt, J., Ott, C. J., Johnstone, R. W., & Bradner, J. E. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2016.148 · Cited by 97
Self-citationKaroor, V., Strassheim, D., Sullivan, T., Verin, A. D., Umapathy, N. S., Dempsey, E. C., Frank, D. N., Stenmark, K. R., & Gerasimovskaya, E. V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189916 · Cited by 98
“HDAC inhibitors, commonly known as a class of anti-cancer agents [14], have been recently found to have therapeutic benefits in PH and other cardiovascular diseases [15,16].”
BackgroundNano-enabled colorectal cancer therapy
Pan, Q., Xi, F., Xie, L. W., Wu, D., Liu, R., Gao, W., Luo, K., He, B., & Pu, Y. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.014 · Cited by 93
Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives
Croce, M., Ferrini, S., Pfeffer, U., & Gangemi, R. M. R. (2019) · Cancers · doi:10.3390/cancers11060846 · Cited by 100
“Human HDACs are divided into four classes, displaying different sensitivity to synthetic inhibitors, and play a relevant role as epigenetic modifiers in cancer [74].”
BackgroundHistone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells
Montani, M. S. G., Granato, M., Santoni, C., Porto, P. D., Merendino, N., D’Orazi, G., Faggioni, A., & Cirone, M. (2017) · Cellular Oncology · doi:10.1007/s13402-017-0314-z · Cited by 96
New Insights into the Epigenetics of Hepatocellular Carcinoma
Wahid, B., Ali, A., Rafique, S., & Idrees, M. (2017) · BioMed Research International · doi:10.1155/2017/1609575 · Cited by 104
Epithelial Barrier in the Nasal Mucosa, Related Risk Factors and Diseases
Zhang, R., Zhang, L., Li, P., Pang, K., Liu, H., & Tian, L. (2023) · International Archives of Allergy and Immunology · doi:10.1159/000528969 · Cited by 104
Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy
Yuan, Z., Chen, S., Sun, Q., Wang, N., Li, D., Miao, S., Gao, C., Chen, Y., Tan, C., & Jiang, Y. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.05.058 · Cited by 91
Aberrant lysine acetylation in tumorigenesis: Implications in the development of therapeutics
Kaypee, S., Sudarshan, D., Shanmugam, M. K., Mukherjee, D., Sethi, G., & Kundu, T. K. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.01.011 · Cited by 97
Epigenetics in Cancer: A Hematological Perspective
Stahl, M. F., Kohrman, N., Gore, S. D., Kim, T. K., Zeidan, A. M., & Prébet, T. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006193 · Cited by 98
HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications
Harada, T., Ohguchi, H., Grondin, Y., Kikuchi, S., Sagawa, M., Tai, Y.-T., Mazitschek, R., Hideshima, T., & Anderson, K. C. (2017) · Leukemia · doi:10.1038/leu.2017.144 · Cited by 89
Metadata
- Authors
- Falkenberg, K. J., & Johnstone, R. W.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- The University of Melbourne (AU)
- Corresponding author
- Johnstone, Ricky W.
- ORCID
- Johnstone, Ricky W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-08-18
- Volume
- 13
- Issue
- 9
- Pages
- 673-691
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2046345187
- Cited by
- 1,564
- References
- 281
- Citations by year
- 2026: 82 · 2025: 110 · 2024: 89 · 2023: 96 · 2022: 121 · 2021: 133 · 2020: 160 · 2019: 146 · 2018: 134 · 2017: 166 · 2016: 208 · 2015: 108 · 2014: 8
- FWCI
- 15.82
- Type
- journal article
- Language
- en
- Update notices
- addendum (2015-02-27)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase, histone deacetylase inhibitors, epigenetic regulation, cancer, neurological disorders, immune disorders, small molecule inhibitors, lysine deacetylation, epigenetic aberrations, drug development
- MeSH terms
- Animals, Histone Deacetylases, Humans, Immune System Diseases, Neoplasms, Nervous System Diseases, Epigenesis, Genetic, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.